HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer[1].
Molecular Weight:
488.62
Purity:
96.54
CAS Number:
[3034605-72-3]
Formula:
C29H36N4O3
Target:
Akt,Apoptosis,EGFR,HSP,Survivin
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
